checkAd
    Phio Pharmaceuticals Corporation Aktie
    0,8197
     
    USD
    +5,67 %
    +0,0440 USD
    Letzter Kurs 02:00:00 Nasdaq
    0,8194
     
    USD
    100 STK
    Geldkurs 03.05.24
    0,8197
     
    USD
    200 STK
    Briefkurs 03.05.24
    ISIN: US71880W4024 · WKN: A3D451 · SYM: PHIO · USA

    Neueste Nachrichten

    Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
    30.04.24 · globenewswire · Phio Pharmaceuticals Corporation
    Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
    22.04.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
    16.04.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
    11.04.24 · globenewswire · Phio Pharmaceuticals Corporation
    National Spotlight Features Phio’s Innovative RNAi Technology Platform
    03.04.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
    02.04.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
    21.03.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
    13.03.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
    06.03.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
    31.01.24 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
    09.11.23 · globenewswire · Phio Pharmaceuticals Corporation
    Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
    09.11.23 · globenewswire · Phio Pharmaceuticals Corporation